Subdermal Contraceptive Implants Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Subdermal Contraceptive Implants Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The Subdermal Contraceptive Implants market is expected to grow with a CAGR of 3.5% during the forecast period (2022 - 2027).

The COVID-19 pandemic has impacted the growth of the studied market. Initially, the global COVID-19 outbreak and the lockdown scenario in various countries have imposed some challenges on the market, as hospitals and clinics were forced to suspend services to prevent the spread of the SARS-CoV-2 virus. The restrictions imposed by the government have significantly impacted the growth of the studied market during the initial period of a pandemic. For instance, according to United Nations Population Fund, in March 2021, the COVID-19 epidemic has disrupted family planning services for an estimated 12 million women, resulting in 1.4 million unplanned pregnancies. In addition to this, During the initial lockdown, women were nine times more likely to have difficulty accessing contraception, resulting in an almost doubling of unexpected births, from 1.3 percent pre-lockdown to 2.1 percent post-lockdown. Additionally, a research study conducted by the United Nations Sexual and Reproductive Health Agency (UNFPA) in 2020 projected that more than 47 million women could lose access to contraception leading to 7 million unintended pregnancies as a result of the COVID-19 crisis. The devastating result of unintended pregnancy is an increase in maternal and neonatal morbidity and mortality. Similarly, a research study by Amanda Black et al., published in Society of Obstetricians and Gynaecologists of Canada (SOGC) 2020, stated that Canadian people and couples who want to avoid pregnancy during the COVID-19 pandemic 2020 are at increased risk of developing an unmet need for family planning due to lack of access to contraceptive care or methods. Adding to this, social isolation may increase unintended pregnancy through exposure to unprotected intercourse, reproductive coercion, and intimate personal violence. Thus, there is an overall negative impact on the studies market due to the COVID-19 pandemic.

Certain factors that are driving the market growth include the increasing number of unwanted pregnancies and the rising number of initiatives to promote contraceptive methods. The number of unwanted pregnancies is increasing globally, and it is a matter of serious concern all around the world. For instance, according to the United Nations Population Fund, in March 2022, unintended pregnancies accounted for about half of all pregnancies worldwide, with 121 million occurring each year. As per the same source, over 60% of unplanned pregnancies end in abortion, with an estimated 45% of all abortions being unsafe, resulting in 5–13% of all maternal fatalities, putting the world's capacity to meet the Sustainable Development Goals at risk. Similarly, according to an article published by the National Center for Biotechnology Information in June 2020, titled "Factors associated with the Unplanned Pregnancy at Suhul General Hospital, Northern Ethiopia, 2018", it has been observed that unplanned pregnancy is one of Ethiopia's biggest reproductive health issues, with all of its negative consequences. Every year, on average, 4.93 million pregnancies occur, with 1.9 million Ethiopian women (38%) having an unintended pregnancy, of which 620,296 induced abortions were performed, and 103,648 women treated for abortion-related complications. Hence, with the increasing rate of unintended pregnancies, there will be a rapid increase in the demand for contraceptive devices, which will ultimately drive the market.

Furthermore, there are countries and their respective governments that have identified the need to curb the growth of unwanted pregnancies and have started a great number of initiatives to educate and prevent the spread of unwanted abortions and pregnancies. The usage of contraceptive pills is one of them. The right to obtain and use contraceptives is part of the fundamental right to privacy guaranteed by United States Constitution. For instance, United States Agency for International Development (USAID) promotes and supports voluntary family planning and reproductive health initiatives in approximately 40 countries throughout the world. Thus, government initiatives are also promoting the use of contraceptive methods to avoid unnecessary births and abortions.

However, the rising prevalence of infertility and lack of awareness and adverse effects of contraceptive implants are likely to restrain the market growth.

The Etonogestrel Implant Segment is expected to witness significant growth over a forecast period owing to the factors such as high clinical effectiveness and high adoption rate. Etonogestrel is a hormone that prevents ovulation. This medication also causes changes in the cervical mucus and uterine lining, making it harder for sperm to reach the uterus and harder for a fertilized egg to attach to the uterus. Subdermal Etonogestrel implant is used as contraception to prevent pregnancy. The medicine is contained in a small plastic rod that is implanted under the skin of the upper arm. The medicine is released slowly into the body. The rod can remain in place and provide continuous contraception for up to 3 years.

The increasing company focus on adopting various business strategies such as product launches, listing products in the countries, mergers, and company spin-offs are likely to boost the growth of the market over the forecast period. For instance, in June 2021, Merck spun off Organon to make it an independent Women's Health company. The company will operate in women's healthcare with a portfolio of contraceptive and fertility brands, dermatology, respiratory, and bone health products. In addition, in January 2022, Organon announced the public listings for NEXPLANON (etonogestrel extended-release subdermal implant) in Ontario (Ontario Drug Benefit Program), British Columbia (BC PharmaCare), and Nova Scotia (Nova Scotia PharmaCare). Similarly, in November 2021, Organon announced the public listings for NEXPLANON (etonogestrel extended-release subdermal implant) in Quebec under the Régie de l'assurance Maladie du Québec (RAMQ).

Thus, the increasing approvals are likely to increase the etonogestrel implant segment, thereby increasing the market growth over the forecast period.

North America is expected to dominate the global viscosupplementation market over the forecast period, owing to the factors such as rising cases of unwanted pregnancies and high abortion rates, increased awareness about contraceptives, and technological advancements, as well as supportive government schemes.

The rising incidences of unwanted pregnancies and abortion rates are the key factor driving the market growth in the region. For instance, according to the Guttmacher Institute, in March 2022, there were a total of 5,660,000 pregnancies annually between 2015 and 2019, of which 2,590,000 were unwanted, and 886,000 resulted in abortion in North America. As per the same source, in Canada, there were a total of 570,000 pregnancies annually between 2015 and 2019, of which 265,000 were unwanted, and 97,500 resulted in abortion. Thus, the increasing cases of unwanted pregnancies and abortion rates are likely to increase the demand for subdermal contraceptive implants, thereby increasing the market growth.

Several organizations are also engaged in the implementation of strategic initiatives in the country. For instance, as per the Bill & Melinda Gates Foundation data published in 2022, the foundation is aiming to offer USD 280 million per year from 2021 to 2030 for developing new and improved contraceptive technologies, support family planning programs that reflect the preferences of local communities, and enable women and girls to be in control of their contraceptive care. Similarly, in June 2019, the Canadian government is planning to increase financing to USD 1.4 billion per year, starting in 2023, to assist women's and girls' health around the world. This financing level, which is supported by the country's Feminist International Assistance Policy, represents a significant increase over a previous three-year investment of CA USD 650 million (2017–2020).

Thus, the rising incidences of unwanted pregnancies and abortion rates and the aforementioned developments are anticipated to boost the adoption of subdermal contraceptive implants in the country, thereby boosting the market growth.

The global Subdermal Contraceptive Implants market is competitive and consists of very few major players. Some of the key companies are Organon, Shanghai Dahua Pharmaceutical Co., Ltd., and Bayer AG, which hold a substantial market share in the market.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support